GlassScriptPhysician profile
Shirley Renee Brown
NPI 1841885449
$2,829.39
in general payments reported to CMS, 2019-2025
15 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.38 · 2022: $248 · 2023: $736 · 2024: $281 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $497.52 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $376.50 | 2021-2025 | Aristada, Aristada Initio, Lybalvi |
| Abbvie INC. | $249.55 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.31 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $207.81 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $203.07 | 2022-2025 | Uzedy |
| Axsome Therapeutics, INC. | $202.69 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $186.92 | 2022-2023 | Ingrezza |
| Syndax Pharmaceuticals, INC. | $129.37 | 2025 | Revuforj |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $111.39 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $105.13 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Dexcom, INC. | $103.88 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Indivior INC. | $51.78 | 2022-2024 | Perseris |
| Lundbeck LLC | $31.47 | 2023 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.